Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.

1 Market-Beating Stock to Buy Near Its 52-Week High

Novo Nordisk

Realty Income Corp

Vertex Pharmaceuticals

Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.

4 Ways to Grow $100,000 Into $1 Million for Retirement

Leadership from Eli Lilly and Novo Nordisk have alluded that it could take several quarters or even years to catch up with demand. Both companies are ratcheting up supply output, which will likely lead to high manufacturing costs.

1 Thing You'd Better Know Before You Invest in the Stocks Behind Ozempic and Mounjaro

Visa

The hunt for the next trillion-dollar companies invariably ignites investor excitement. Moreover, the AI-led excitement in equities this year pushed tech stocks to new highs while others reversed the losses from the past year.

The Next Trillion-Dollar Companies: 3 Stocks to Buy Now

The pending acquisition reflects the potential of Mablink's existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates.

Mablink Bioscience Enters an Agreement to be Acquired by Lilly

Eli Lilly & Co (NYSE: LLY) is buying Mablink Bioscience – a French biotechnology company that focuses primarily on the next-generation, antibody-drug conjugates for cancer. It's the 2nd cancer company Lilly bought this month Clearly, the pharmaceutical behemoth is committed to expanding its footprint in oncology.

Eli Lilly is buying another European cancer firm Mablink Bioscience

DexCom

Edwards Lifesciences

iShares U.S. Medical Devices ETF

Inspire Medical Systems Inc

Intuitive Surgical

Insulet

ResMed

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

Novo Nordisk recently raised its full-year 2023 guidance in large part because of greater sales expectations for Ozempic. The same dynamics behind Ozempic's success are also helping Lilly's Mounjaro.

Ozempic Sales Are Skyrocketing Faster Than Expected. Here's Why That's Great News for Eli Lilly Stock.

Alphabet

Microsoft

NVIDIA

Tesla

Taiwan Semiconductor Manufacturing

They say we're now living in an “age of acceleration” when technological advances are coming at us at breakneck speed. Not long ago, science fiction films and novels depicted a future when we would speak to computers and they would speak back, people would take a pill each day to remain thin and private companies would shuttle astronauts and supplies into space.

7 Cutting-Edge Stocks That Could Change Humanity as We Know It

The full results of the SURMOUNT-3 trial were published in Nature Medicine and simultaneously presented at ObesityWeek ®  2023 INDIANAPOLIS , Oct. 15, 2023 /PRNewswire/ -- Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in Nature Medicine  and simultaneously presented at ObesityWeek® 2023. Tirzepatide met both co-primary endpoints for the efficacy estimandi and treatment-regimenii estimand, demonstrating superiority to placebo during the 72-week double-blind treatment period.

Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks

Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.

Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals

Campbell Soup

General Mills

Hershey

Kellogg

Kraft Heinz

Mondelez

McCormick

Invesco Dynamic Food & Beverage ETF

J. M. Smucker

Simply Good Foods

Tyson Foods

Hostess Brands

Consumer Staples Select Sector SPDR Fund

Bernstein analysts set out to determine that, analyzing online data to better understand changes in eating habits — and to evaluate which food companies may be most affected. They published the results in a report Friday.

What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.

Hormel Foods

Coca-Cola

PepsiCo

1 Dividend Legend Potentially Set To Soar And 2 To Ignore

Birkenstock Holding Plc

Costco

Intel

McDonald's

Stellantis N.V. 

Walgreens

The Social Security cost of living adjustment (COLA), which is tied to the rate of inflation, was a whopping 8.7% this year. It is expected to be around 3.2% for 2024.

7 Stocks to Buy With Your 2024 Social Security Increase

Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.

Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Lilly (LLY) Moves 4.5% Higher: Will This Strength Last?

Eli Lilly, Coca-Cola, and Microsoft are solid dividend stocks that have grown their payouts for years. Moreover, these are highly profitable companies whose dividends still have plenty of room to rise.

3 Super Safe Dividend Stocks That Have Been Making Payments for Decades

Amazon

SPDR S&P 500 ETF Trust

Seeking Alpha's quant computer ranking tool identifies Amazon, NVIDIA, Tesla, Eli Lilly, and Visa as the most overvalued mega-cap stocks. Earnings, EBITDA, book value, and dividend yields as value backstops are lacking for prudent investors at current price levels. If a recession is next, I fully expect these 5 stocks as a group to both underperform the S&P 500 index and strip investors of considerable wealth.

5 Most Overvalued Mega-Caps According To Quant: Buy, Sell, Hold?

Eli Lilly and Co (NYSE:LLY) announced on Thursday that its drug development candidate, mirikizumab, met the main goals of a late-stage study to test it as a treatment for moderately to severely active Crohn's disease, which causes inflammation in the digestive tract.  The drug maker said mirikizumab helped 54.1% of the patients achieve a state where they were no longer experiencing any gastrointestinal symptoms after 52 weeks, compared with 19.6% who received the placebo.

Eli Lilly stock hits new high on positive Crohn's disease study results

Eli Lilly (NYSE: LLY) stock price has quietly become one of the best-performing stocks in the past few years. The shares are trading at their all-time high of $605.28, higher than the 2009 low of $14.

Eli Lilly (LLY) stock price is flying: buy the Nvidia of pharma

Conagra Brands

Walmart

But does Novo Nordisk's good fortune translate to lower sales for companies like Walmart Inc. NYSE: WMT, Coca-Cola Co. NYSE: KO and PepsiCo Inc. NASDAQ: PEP?

Will Higher Ozempic Use Mean Slimmed-Down Food Sales?

Eli Lilly said on Thursday its experimental drug met the main goals of a late-stage study to test it as a treatment for moderately to severely active Crohn's disease, a type of inflammatory bowel disease.

Lilly's bowel disease drug succeeds in late-stage study

Mirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks The study achieved the coprimary endpoints and all major secondary endpoints versus placebo This successful Phase 3 trial will be the basis of global regulatory submissions for Crohn's disease INDIANAPOLIS , Oct. 12, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn's disease. The double-blind, treat-through trial included mirikizumab, placebo and active control (ustekinumab) arms.

News for Eli Lilly Stock (LLY)